ArticleThe Journal of rheumatology2011
Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.
Article in The Journal of rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12.The Journal of rheumatology · 2015Pooled it
- Outcome measures used in clinical trials for Behçet syndrome: a systematic review.The Journal of rheumatology · 2014Pooled it
- Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.Clinical rheumatology · 2014Pooled it
- A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis.Arthritis & rheumatology (Hoboken, N.J.) · 2017Trial
- A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.Arthritis & rheumatology (Hoboken, N.J.) · 2017Trial
- Patient-reported outcomes and disease activity in giant cell arteritis: a longitudinal registry-based study.Rheumatology (Oxford, England) · 2026Article
- Development of outcome measures for giant cell arteritis for use in clinical trials and standard practice.Clinical rheumatology · 2023Article
- Vascular Uptake onYonsei medical journal · 2021Article
- Article
- Patient Reported Outcomes in Large Vessel Vasculitides.Current rheumatology reports · 2021Review
- Childhood-onset Takayasu Arteritis.European journal of rheumatology · 2020Article
- Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis.The Journal of rheumatology · 2020Observational
- Mechanism and biomarkers in aortitis--a review.Journal of molecular medicine (Berlin, Germany) · 2020Review
- Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018.The Journal of rheumatology · 2019Article
- Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis.The Journal of rheumatology · 2019Article
- Arterial lesions in giant cell arteritis: A longitudinal study.Seminars in arthritis and rheumatism · 2019Article
- Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes.Patient related outcome measures · 2019Review
- Unmet Needs in the Pathogenesis and Treatment of Vasculitides.Clinical reviews in allergy & immunology · 2018Review
- Observational
- Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016.The Journal of rheumatology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 5 countries.
Funding
Abstract
Giant cell (GCA) and Takayasu's arteritis (TAK) are 2 forms of large-vessel vasculitis (LVV) that involve the aorta and its major branches. GCA has a predilection for the cranial branches, while TAK tends to affect the extracranial branches. Both disorders may also cause nonspecific constitutional symptoms. Although some clinical features are more common in one or the other disorder and the ages of initial presentation differ substantially, there is enough clinical and histopathologic overlap between these disorders that some investigators suggest GCA and TAK may be 2 processes within the spectrum of a single disease. There have been few randomized therapeutic trials completed in GCA, and none in TAK. The lack of therapeutic trials in LVV is only partially explained by the rarity of these diseases. It is likely that the lack of well validated outcome measures for LVV and uncertainties regarding trial design contribute to the paucity of trials for these diseases. An initiative to develop a core set of outcome measures for use in clinical trials of LVV was launched by the international OMERACT Vasculitis Working Group in 2009 and subsequently endorsed by the OMERACT community at the OMERACT 10 meeting. Aims of this initiative include: (1) to review the literature and existing data related to outcome assessments in LVV; (2) to obtain the opinion of experts and patients on disease content; and (3) to formulate a research agenda to facilitate a more data-based approach to outcomes development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.